<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424304</url>
  </required_header>
  <id_info>
    <org_study_id>C-17-EV12</org_study_id>
    <nct_id>NCT03424304</nct_id>
  </id_info>
  <brief_title>Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment</brief_title>
  <official_title>Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera Excel V™ Laser With Green Genesis and a Micro-Lens Array Attachment as Compared to the Standard-of-care With an Excel V™ Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array (MLA) Attachment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, prospective, single-center, split-face Feasibility study to Evaluate
      1) the safety and efficacy of the Cutera excel V™ laser and the Micro-Lens Array attachment
      to the Genesis V hand piece, and 2) the safety and efficacy of the Cutera excel V™ laser
      Green Genesis V hand piece to the CoolView hand piece.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photo Assessment of Improvement #1</measure>
    <time_frame>Baseline and 12 weeks post final treatment</time_frame>
    <description>Correct photo identification measuring improvement, comparing Baseline photos to 12 weeks post final laser treatment photos, as assessed by three blinded assessors in at least 75% of the subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Improvement #2</measure>
    <time_frame>Baseline and 12 weeks post-final treatment</time_frame>
    <description>The improvement after treatment from Baseline of ≥1 on the Global Aesthetic Improvement Scale (GAIS), as assessed by three blinded assessors in at least 75% of subjects. GAIS:+4=Very Significant Improvement (≥75%),+3=Significant Improvement(50-74%), +2=Moderate Improvement(25 - 49%), +1=Mild Improvement(5-24%), and 0=No Change(&lt; 5%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement #1 of device Adverse Effects (AE)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety of the Cutera excel V laser with Green Genesis and Micro-Lens Array (MLA) Attachment as assessed by frequency and severity (0=none, 1=mild, 2=moderate, or 3=severe) of device related adverse events as reported up to the 12 week follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement #2 of device Adverse Effects (AE)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety of the Cutera excel V laser with Micro-Lens Array attachment as assessed by frequency and severity (0=none, 1=mild, 2=moderate or 3=severe) of device adverse events as reported up to the 12 week follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement #3 of skin quality</measure>
    <time_frame>2 to 4 weeks after third treatment and12 weeks post-final treatment</time_frame>
    <description>Efficacy of the Cutera excel V laser with Green Genesis to diffuse facial redness and/or improve dyschromia (pigment) as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit, using Skin Quality Rating Scale (1-10): for Radiance, Smoothness, Pigmentation, Erythema and Pore size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement #4 of wrinkles</measure>
    <time_frame>2 to 4 weeks after third treatment and12 weeks post-final treatment</time_frame>
    <description>Efficacy of the Cutera excel V laser with the Micro-Lens Array to treat fine lines and skin texture, as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit using the Fitzpatrick Wrinkle Classification System (FWCS): (1-3=fine wrinkles, 4-6=moderate depth &amp; moderate number of lines, and 7-9=severe depth &amp; numerous lines)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement #4 of acne scarring</measure>
    <time_frame>2 to 4 weeks after third treatment and12 weeks post-final treatment</time_frame>
    <description>Efficacy of the Cutera excel V laser with the Micro-Lens Array to improve acne scar severity as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit, using Acne Scar Assessment Scale (ASAS): (+1=clear, +2=very mild, +3=mild, +4=moderate, and 5=severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Wrinkle</condition>
  <condition>Rosacea</condition>
  <condition>Scarring</condition>
  <arm_group>
    <arm_group_label>Excel V™ Laser With Green Genesis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excel V™ Laser With Green Genesis</intervention_name>
    <description>Subject(s) will receive 3 to 5 treatments with a Cutera Excel V™ Laser</description>
    <arm_group_label>Excel V™ Laser With Green Genesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be able to read, understand and sign the Informed Consent Form.

          2. Female or Male, 18 to 65 years of age (inclusive).

          3. Fitzpatrick Skin Type I - VI (Appendix 4).

          4. Must be willing to have Cutera excel V laser treatments with MLA and/or Green Genesis
             (532 nm) and able to adhere to the treatments, follow-up visit schedule, and
             post-treatment care instructions.

          5. Willing to have very limited sun exposure and use sunscreen on the treatment area
             every day for the duration of the study, including the follow-up period.

          6. Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation (educational and/or marketing), publications, and any
             additional marketing purposes.

          7. Agree to not undergo any other cosmetic procedure(s) or treatment(s) on the face
             during the study and has no intention of having such procedures performed during the
             course of the study.

          8. For female subjects: not pregnant or lactating and is either post-menopausal,
             surgically sterilized, or using a medically acceptable form of birth control at least
             3 months prior to enrollment and during the entire course of the study.

        Exclusion Criteria:

          1. Participation in a clinical trial of another drug, or device administered to the
             treatment area, within 3 months prior to enrollment or during the study.

          2. Any type of prior cosmetic treatment to the target area within 3 months of study
             participation, such as laser procedures, facial fillers, toxins and those used for
             general aesthetic correction.

          3. Use of prescription topicals in the treatment area within one month prior to treatment
             or use of topical agents one week prior to treatment that may cause facial
             sensitivity.

          4. Suffering from significant skin conditions in the treated areas or inflammatory skin
             conditions, including but not limited to, open lacerations or abrasions, hidradenitis,
             rash, infection , or dermatitis of the treatment area prior to treatment (duration of
             resolution as per the Investigator's discretion).

          5. Pregnant and/or breastfeeding, or planning to become pregnant.

          6. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune
             deficiency disorders (including HIV infection or AIDS) or using immunosuppressive
             medication.

          7. Hypersensitivity to light exposure.

          8. Any use of medication that is known to increase sensitivity to light according to the
             Investigator's discretion.

          9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone
             to bruising.

         10. Has a history of squamous cell carcinoma or melanoma in the treatment area.

         11. History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity), including collagen vascular disease or vasculitic disorders.

         12. A history or active skin condition that in the opinion of the Investigator may
             interfere/confound with the treatment.

         13. History of connective tissue disease, such as systemic lupus erythematosus or
             scleroderma.

         14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes
             zoster (shingles) in the treatment area, unless treatment is conducted following a
             prophylactic regimen.

         15. History of pigmentary disorders, particularly tendency for hyper- or hypo-
             pigmentation, or any that are considered not acceptable by the study investigator.

         16. Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of equal to,
             or greater than 10,000 units per day) within 12 months of initial treatment or plans
             on using during the course of the study (note: skin must regain its normal degree of
             moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).

         17. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely
             to refrain from tanning during the study.

         18. Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,)
             that would interfere with diagnosis, assessment, and treatment.

         19. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study, including excessive
             alcohol or drug abuses, or a condition that would compromise the subject's ability to
             comply with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ronan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cutera Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cutera Research Center</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

